当前位置:首页 - 行情中心 - 乐心医疗(300562) - 财务分析 - 利润表

乐心医疗

(300562)

  

流通市值:24.17亿  总市值:32.62亿
流通股本:1.61亿   总股本:2.17亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入273,307,188.91983,982,436.12756,340,201.33498,597,682.17
营业收入273,307,188.91983,982,436.12756,340,201.33498,597,682.17
二、营业总成本246,632,304.47908,152,076.03698,416,206.35458,106,247.35
营业成本171,149,117.44638,873,788.26482,104,867.66316,085,313.35
税金及附加1,960,770.957,875,594.376,018,472.424,032,857.01
销售费用26,880,221.0993,808,201.6280,693,00054,874,117.92
管理费用22,739,145.7788,443,748.3162,741,488.1940,353,968.2
研发费用26,345,008.6496,807,528.0774,604,037.6851,556,890.94
财务费用-2,441,959.42-17,656,784.6-7,745,659.6-8,796,900.07
其中:利息费用819,716.085,346,679.632,616,202.631,659,586.92
其中:利息收入781,204.577,349,831.585,857,930.693,038,159.19
加:公允价值变动收益1,306,601.23-136,535.03-4,109,938.26-2,353,294.21
加:投资收益-702,911.05302,371.39649,977.752,139,122.88
资产处置收益49,062.2690,332.76-83,938.47-75,901.4
资产减值损失(新)--19,326,754.33-2,244,438.35-2,244,438.35
信用减值损失(新)-3,935,111.3-1,216,344.28-5,478,539.72-6,042,302.74
其他收益665,150.222,877,223.942,895,895.192,158,081.74
营业利润平衡项目0000
四、营业利润24,057,675.858,420,654.5449,553,013.1234,072,702.74
加:营业外收入2,001.72,148,817.81778,073.04761,572.89
减:营业外支出52,374.44530,001.04476,859.49475,583.05
利润总额平衡项目0000
五、利润总额24,007,303.0660,039,471.3149,854,226.6734,358,692.58
减:所得税费用1,221,307.271,883,240.861,668,135.361,453,023.65
六、净利润22,785,995.7958,156,230.4548,186,091.3132,905,668.93
持续经营净利润22,785,995.7958,156,230.4548,186,091.3132,905,668.93
归属于母公司股东的净利润22,942,005.9661,364,226.2750,527,301.9834,849,732.47
少数股东损益-156,010.17-3,207,995.82-2,341,210.67-1,944,063.54
(一)基本每股收益0.110.280.230.16
(二)稀释每股收益0.110.280.230.16
八、其他综合收益-641.48-54,794,563.4119,633.15433,798.78
归属于母公司股东的其他综合收益-641.48-54,794,563.4119,633.15433,798.78
九、综合收益总额22,785,354.313,361,667.0548,305,724.4633,339,467.71
归属于母公司股东的综合收益总额22,941,364.486,569,662.8750,646,935.1335,283,531.25
归属于少数股东的综合收益总额-156,010.17-3,207,995.82-2,341,210.67-1,944,063.54
公告日期2025-04-262025-03-292024-10-292024-08-09
审计意见(境内)标准无保留意见
TOP↑